Gilead Sciences, Inc. (GILD) said that aztreonam for inhalation solution, an investigational product for the treatment of infections due to Pseudomonas aeruginosa in patients with cystic fibrosis, is scheduled to be reviewed by the Anti-Infective Drugs Advisory Committee of the U.S. Food and Drug Administration on December 10, 2009.
In September 2009, the product was granted conditional marketing approval in Canada and Europe under the trade name Cayston. Applications for marketing approval of Cayston are also pending in Australia, Switzerland and Turkey, the company noted.
For comments and feedback: editorial@rttnews.com